"The
Report Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC
2.7.10.2) - Pipeline Review, H2 2016 provides information on pricing,
market analysis, shares, forecast, and company profiles for key
industry participants. - MarketResearchReports.biz"
Global
Markets Directs, Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1
or EC 2.7.10.2) - Pipeline Review, H2 2016, provides in depth
analysis on Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or
EC 2.7.10.2) targeted pipeline therapeutics.
The
report provides comprehensive information on the Tyrosine Protein
Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) , targeted
therapeutics, complete with analysis by indications, stage of
development, mechanism of action (MoA), route of administration (RoA)
and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally,
the report provides an overview of key players involved in Tyrosine
Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted
therapeutics development and features dormant and discontinued
projects.
View Report At
http://www.marketresearchreports.biz/analysis/794363
Global
Markets Directs report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global
Markets Directs proprietary databases, company/university websites,
clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles
featured in the report undergoes periodic review following a
stringent set of processes to ensure that all the profiles are
updated with the latest set of information. Additionally, various
dynamic tracking processes ensure that the most recent developments
are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities
and helps to create effective counter strategies to gain competitive
advantage.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/794363
Scope
-
The report provides a snapshot of the global therapeutic landscape
for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC
2.7.10.2)
-
The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or
JAK1 or EC 2.7.10.2) targeted therapeutics under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved in Tyrosine Protein Kinase
JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics
and enlists all their major and minor projects
-
The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or
JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of
action (MoA), route of administration (RoA) and molecule type
-
The report summarizes all the dormant and discontinued pipeline
projects
-
The report reviews latest news and deals related to Tyrosine Protein
Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted
therapeutics
Reasons to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand the targeted therapy areas and indications
for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC
2.7.10.2)
-
Identify the use of drugs for target identification and drug
repurposing
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Plan mergers and acquisitions effectively by identifying key players
and its most promising pipeline therapeutics
-
Devise corrective measures for pipeline projects by understanding
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
development landscape
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
Table
of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report
Coverage 8
Tyrosine Protein Kinase JAK1
(Janus Kinase 1 or JAK1 or EC 2.7.10.2) Overview 9
Therapeutics Development 10
Tyrosine Protein Kinase JAK1
(Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Products under Development
by Stage of Development 10
Tyrosine Protein Kinase JAK1
(Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Products under Development
by Therapy Area 11
Tyrosine Protein Kinase JAK1
(Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Products under Development
by Indication 12
Tyrosine Protein Kinase JAK1
(Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Tyrosine Protein Kinase JAK1
(Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Products under Development
by Companies 17
Tyrosine Protein Kinase JAK1
(Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment 24
Assessment by
Monotherapy/Combination Products 24
Assessment by Mechanism of Action
25
Assessment by Route of
Administration 26
Assessment by Molecule Type 28
Tyrosine Protein Kinase JAK1
(Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in
Therapeutics Development 29
AbbVie Inc. 29
Aclaris Therapeutics, Inc. 30
Advinus Therapeutics Ltd 31
Astellas Pharma Inc. 32
AstraZeneca Plc 33
Chipscreen Biosciences Ltd 34
CJ HealthCare Corp. 35
Concert Pharmaceuticals, Inc. 36
Eli Lilly and Company 37
Galapagos NV 38
Gilead Sciences, Inc. 39
Incyte Corporation 40
Nissan Chemical Industries, Ltd.
42
Pfizer Inc. 43
Portola Pharmaceuticals, Inc. 44
Sareum Holdings Plc 45
Theravance Biopharma, Inc. 46
Vectura Group Plc 47
Tyrosine Protein Kinase JAK1
(Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles 48
(INCB-039110 + INCB-040093) - Drug
Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
ATI-50001 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ATI-50002 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment